WAVE Life Sciences (NASDAQ:WVE) Now Covered by HC Wainwright

Equities research analysts at HC Wainwright assumed coverage on shares of WAVE Life Sciences (NASDAQ:WVE) in a report released on Wednesday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2027 earnings at ($0.28) EPS.

Several other research firms also recently commented on WVE. Wall Street Zen downgraded shares of WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. began coverage on shares of WAVE Life Sciences in a research report on Wednesday, September 23rd. They set a “neutral” rating for the company. Zacks Research lowered WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. Finally, Citigroup dropped their price objective on shares of WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating for the company in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.89.

WAVE Life Sciences Stock Up 5.5%

NASDAQ WVE opened at $3.64 on Wednesday. WAVE Life Sciences has a 52 week low of $3.04 and a 52 week high of $21.73. The company has a fifty day moving average of $4.13 and a two-hundred day moving average of $7.60. The firm has a market capitalization of $717.92 million, a price-to-earnings ratio of -3.34 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $13.16 million during the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. Equities research analysts anticipate that WAVE Life Sciences will post -1.12 EPS for the current year.

Insider Buying and Selling

In related news, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total value of $42,070.00. Following the completion of the transaction, the director owned 44,930 shares in the company, valued at approximately $270,029.30. The trade was a 13.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of WAVE Life Sciences stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The disclosure for this sale is available in the SEC filing. Insiders sold 23,564 shares of company stock valued at $132,476 in the last 90 days. Company insiders own 24.34% of the company’s stock.

Institutional Trading of WAVE Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaGrep UK Ltd purchased a new position in shares of WAVE Life Sciences in the 2nd quarter valued at about $78,000. First Trust Advisors LP boosted its holdings in shares of WAVE Life Sciences by 15.7% during the first quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock worth $98,000 after purchasing an additional 1,830 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new position in shares of WAVE Life Sciences during the 1st quarter valued at about $124,000. Gabelli Funds LLC acquired a new position in shares of WAVE Life Sciences in the 1st quarter valued at $127,000. Finally, Seven Fleet Capital Management LP acquired a new position in WAVE Life Sciences in the second quarter valued at $111,000. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrower than the $0.33–$0.34 analyst consensus. Revenue of $13.16 million also substantially exceeded estimates of approximately $4.51 million, helping ease concerns about the company’s near-term financial performance. Wave Life Sciences Stock Rallies as Q3 Results Ease Loss Fears
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, providing a meaningful future catalyst if the program continues to generate positive data. WAVE Life Sciences Reports Third Quarter Results and Business Update
• Positive Sentiment: Management’s earnings call and business update provided investors with additional detail on the development pipeline and upcoming clinical milestones, supporting optimism around WVE-006 and the company’s broader RNA-editing platform. WAVE Life Sciences Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Oppenheimer reduced its price target to $29 from $32 but maintained an Outperform rating. The lower target is a modest valuation reset, while the unchanged rating indicates the analyst remains constructive on WVE’s long-term prospects. Oppenheimer Adjusts WAVE Life Sciences Price Target
• Negative Sentiment: Despite the earnings beat, WAVE remains unprofitable, reporting a quarterly loss and maintaining substantial cash-burn risk as it funds clinical development. Analysts continue to forecast a full-year loss, leaving the stock highly dependent on future trial progress and financing conditions. WAVE Life Sciences Reports Q3 Loss and Tops Revenue Estimates

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.